SkyePharma success

Published: 28-May-2001


DepoCyte, SkyePharma's treatment for lymphomatous meningitis, has been recommended for approval by the European committee on proprietary medicinal products. The product, cytarabine liposome injection, is an injectable sustained-release formulation that uses SkyePharma's proprietary lipid-based drug delivery technology. It gradually releases cytarabine into the cerebrospinal fluid, extending the dosing interval to once every two weeks. This compares to the standard treatment, requiring intrathecal administration twice a week.

You may also like